Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 31;10(17):3955.
doi: 10.3390/jcm10173955.

GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Physiology to Clinical Outcomes

Alba Rojano Toimil  1 , Andreea Ciudin  1   2   3
Affiliations
Review

GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Physiology to Clinical Outcomes

Alba Rojano Toimil et al. J Clin Med. .

Abstract

Diabetic kidney disease (DKD) is one of the most common complications in type 2 diabetes mellitus (T2D) and a major cause of morbidity and mortality in diabetes. Despite the widespread use of nephroprotective treatment of T2D, the incidence of DKD is increasing, and it is expected to become the fifth cause of death worldwide within 20 years. Previous studies have demonstrated that GLP-1 receptor agonists (GLP-1 RA) have improved macrovascular and microvascular outcomes independent of glycemic differences, including DKD. GLP-1Ras' improvement on kidney physiology is mediated by natriuresis, reduction in hyperfiltration and renin-angiotensin-aldosterone system (RAAS) activity and anti-inflammatory properties. These findings translate into improved clinical outcomes such as an enhanced urine albumin-to-creatinine ratio (UACR) and a reduction in renal impairment and the need for renal replacement therapies (RRT). In this article, we review the role of GLP-1RAs on the mechanisms and effect in DKD and their clinical efficacy.

Keywords: GLP-1 receptor agonists; diabetic kidney disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Muskiet M.H.A., Tonneijck L., Smits M.M., Kramer M.H.H., Heerspink H.J.L., van Raalte D.H. Pleiotropic Effects of Type 2 Diabetes Management Strategies on Renal Risk Factors. Lancet Diabetes Endocrinol. 2015;3:367–381. doi: 10.1016/S2213-8587(15)00030-3. - DOI - PubMed
    1. Nathan D.M. Diabetes: Advances in Diagnosis and Treatment. JAMA. 2015;314:1052–1062. doi: 10.1001/jama.2015.9536. - DOI - PubMed
    1. Gregg E.W., Li Y., Wang J., Rios Burrows N., Ali M.K., Rolka D., Williams D.E., Geiss L. Changes in Diabetes-Related Complications in the United States, 1990–2010. N. Engl. J. Med. 2014;370:1514–1523. doi: 10.1056/NEJMoa1310799. - DOI - PubMed
    1. Gregg E.W., Sattar N., Ali M.K. The Changing Face of Diabetes Complications. Lancet Diabetes Endocrinol. 2016;4:537–547. doi: 10.1016/S2213-8587(16)30010-9. - DOI - PubMed
    1. Thomas M.C., Cooper M.E., Zimmet P. Changing Epidemiology of Type 2 Diabetes Mellitus and Associated Chronic Kidney Disease. Nat. Rev. Nephrol. 2016;12:73–81. doi: 10.1038/nrneph.2015.173. - DOI - PubMed

LinkOut - more resources